핵의학

본문글자크기
  • [PLoS One] Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.

    서울의대 / 박세훈, 하승균, 이세훈*, 팽진철*

  • 출처
    PLoS One
  • 등재일
    2018 Jan 31
  • 저널이슈번호
    13(1):e0189766.
  • 내용

    바로가기  >

    Abstract

    Intratumoral heterogeneity has been suggested to be an important resistance mechanism leading to treatment failure. We hypothesized that radiologic images could be an alternative method for identification of tumor heterogeneity. We tested heterogeneity textural parameters on pretreatment FDG-PET/CT in order to assess the predictive value of target therapy. Recurred or metastatic non-small cell lung cancer (NSCLC) subjects with an activating EGFRmutation treated with either gefitinib or erlotinib were reviewed. An exploratory data set (n = 161) and a validation data set (n = 21) were evaluated, and eight parameters were selected for survival analysis. The optimal cutoff value was determined by the recursive partitioning method, and the predictive value was calculated using Harrell's C-index. Univariate analysis revealed that all eight parameters showed an increased hazard ratio (HR) for progression-freesurvival (PFS). The highest HR was 6.41 (P<0.01) with co-occurrence (Co) entropy. Increased risk remained present after adjusting for initial stage, performance status (PS), and metabolic volume (MV) (aHR: 4.86, P<0.01). Textural parameters were found to have an incremental predictive value of early EGFR tyrosine kinase inhibitor (TKI) failure compared to that of the base model of the stage and PS (C-index 0.596 vs. 0.662, P = 0.02, by Co entropy). Heterogeneity textural parameters acquired from pretreatment FDG-PET/CT are highly predictive factors for PFS of EGFR TKI in EGFR-mutated NSCLC patients. These parameters are easily applicable to the identification of a subpopulation at increased risk of early EGFR TKI failure. Correlation to genomic alteration should be determined in future studies.

     

     

    Author information

    Park S1, Ha S2, Lee SH1,3, Paeng JC2, Keam B1, Kim TM1, Kim DW1, Heo DS1.
    1Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
    2Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University Hospital, Seoul, Republic of Korea.
    3Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

  • 덧글달기
    덧글달기
       IP : 54.166.223.204

    등록